Alpha Fetoprotein - Explore the Science & Experts | ideXlab

Scan Science and Technology

Contact Leading Edge Experts & Companies

Alpha Fetoprotein

The Experts below are selected from a list of 156 Experts worldwide ranked by ideXlab platform

Yinghuang Tsai – 1st expert on this subject based on the ideXlab platform

  • Alpha Fetoprotein measurement benefits hepatocellular carcinoma surveillance in patients with cirrhosis
    The American Journal of Gastroenterology, 2015
    Co-Authors: Te Sheng Chang, Yu Chih Wu, Shui Yi Tung, Yung Yu Hsieh, Hao Chun Huang, Weiming Chen, Chien Heng Shen, Chang Hsien Lu, Cheng Shyong Wu, Yinghuang Tsai


    AlphaFetoprotein Measurement Benefits Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis

Shigenobu Nagataki – 2nd expert on this subject based on the ideXlab platform

  • early recognition of hepatocellular carcinoma based on altered profiles of Alpha Fetoprotein
    The New England Journal of Medicine, 1993
    Co-Authors: Yoshiaki Sato, Kazuhisa Taketa, Y. Endo, Keisuke Nakata, Yuji Kato, Masayoshi Shima, Nobuko Ishii, Toshihiko Koji, Shigenobu Nagataki


    Background The sugar-chain structures of circulating AlphaFetoprotein in patients with hepatocellular carcinomas differ from those in patients with cirrhosis. We studied the reactivity of AlphaFetoprotein with two lectins, Lens culinaris agglutinin A and erythroagglutinating phytohemagglutinin, to monitor the evolution of hepatocellular carcinoma in patients with cirrhosis. Methods Among 361 patients with cirrhosis caused mainly by chronic hepatitis B or hepatitis C virus infection, 33 with base-line serum AlphaFetoprotein concentrations ≥ 30 ng per milliliter were found to have hepatocellular carcinomas during a mean follow-up of 35 months. The lectin-reactive profiles of the AlphaFetoprotein in the serum of these 33 patients were analyzed and compared with those in the serum of 32 patients with cirrhosis who had increased base-line serum AlphaFetoprotein concentrations and were followed for at least 24 months but in whom hepatocellular carcinoma did not develop. Results At the time of tumor detecti…

Yoshiro Matsumoto – 3rd expert on this subject based on the ideXlab platform

  • clinicopathologic features of gastric cancers producing Alpha Fetoprotein
    Digestive Surgery, 2002
    Co-Authors: Koji Kono, Hideki Amemiya, Takayoshi Sekikawa, Hidehiko Iizuka, Akihiro Takahashi, Hideki Fujii, Yoshiro Matsumoto


    Background: Patients with gastric cancers producing AlphaFetoprotein (AFP) were reported to have a poor prognosis with high rates of liver metastasis. The purpose of the present st